Patients with asthma who test positive for SARS-CoV-2 may not have a higher risk of hospitalization or severe outcomes associated with COVID-19 compared with patients without asthma.
In hospitalized patients with coronavirus disease 2019 (COVID-19), ivermectin was associated with lower mortality compared to treatment without the antiparasitic drug.
Treatment with beta-blockers vs amiodarone, calcium channel blockers, or digoxin was associated with improved heart control at 1, but not 6 hours in patients with sepsis and atrial fibrillation.
Prolongation of the QTc interval was found to be prevalent after 7 days of hospitalization for COVID-19.
A literature review assessed English-language studies and case reports that focused on urticaria in patients with COVID-19.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
Investigators sought to evaluate the role of breast milk immunoglobulin A (IgA) in norovirus (NV) infection and diarrhea in infants to determine whether breast milk IgA has a preventive effect against NV infection and subsequent diarrhea.
The American College of Physicians assessed remdesivir use for the treatment of patients with moderate and severe COVID-19 varying by symptom, disease severity, mechanical ventilation, and treatment duration.
Patients with symptomatic severe aortic stenosis who had aortic valve replacement deferred vs expedited at the beginning of the COVID-19 pandemic were more likely to be hospitalized for valve-related symptoms or worsening heart failure.
Approximately 7% of pneumonia cases acquired in the intensive care unit can be classified as Staphylococcus aureus intensive care unit pneumonia.
